Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 80Stomach Neoplasms 64Rectal Neoplasms 39Pancreatic Neoplasms 31Colonic Neoplasms 27Esophageal Neoplasms 24Lymphoma, Large B-Cell, Diffuse 20Adenocarcinoma 19Neoplasms 18Cholangiocarcinoma 16Neoplasm Metastasis 15Adenocarcinoma Of Esophagus 14Biliary Tract Neoplasms 12Carcinoma, Non-Small-Cell Lung 11Parkinson Disease 4, Autosomal Dominant Lewy Body 10Ovarian Neoplasms 10Gastrointestinal Neoplasms 7Gallbladder Neoplasms 7Carcinoma, Hepatocellular 7Esophageal Squamous Cell Carcinoma 6Endometrial Neoplasms 6Locally Advanced Rectal Cancer 5Recurrence 4Lymphoma 4Carcinoma 4Bile Duct Neoplasms 4Advanced Solid Tumors 4Triple Negative Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Peritoneal Neoplasms 3

Interventions

irinotecan sucrosofate 1Oxaliplatin 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Small Intestine Cancer × Oxaliplatin × 1 year × Clear all
NCT07060014 2025-07-11

NALIRIFOX (Nal-IRI Plus 5-FU/LV Plus Oxaliplatin) as First-Line Treatment for Patients With Advanced Small Intestine and Appendiceal Cancers

The Methodist Hospital Research Institute

Phase 1 Not yet recruiting
22 enrolled
Gastrointestinal

Advanced Small Intestine Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡